Mickleton, NJ, United States of America

Hetal Parekh-Olmedo



Average Co-Inventor Count = 2.4

ph-index = 2

Forward Citations = 8(Granted Patents)


Location History:

  • Mantua, NJ (US) (2009)
  • Mickleton, NJ (US) (2010)

Company Filing History:


Years Active: 2009-2010

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Hetal Parekh-Olmedo: Innovator in Genetic Therapeutics

Introduction

Hetal Parekh-Olmedo is a notable inventor based in Mickleton, NJ, who has made significant contributions to the field of genetic therapeutics. With a total of two patents to his name, he is recognized for his innovative approaches to treating complex diseases.

Latest Patents

His latest patents include "G-rich polynucleotides for the treatment of Huntington's Disease," which focuses on oligonucleotide compositions designed to modify protein-protein interactions. This invention specifically addresses the use of guanidine-rich oligonucleotides to disrupt disease-causing protein aggregates associated with Huntington's Disease. Another significant patent is "Enhanced oligonucleotide-mediated nucleic acid sequence alteration," which is directed towards the repair or alteration of genetic information. This invention incorporates various factors, such as Histone Deacetylase Inhibitor (HDAC), Lambda phage beta protein, or hydroxyurea, to enhance the efficiency of genetic alterations.

Career Highlights

Hetal Parekh-Olmedo is affiliated with the University of Delaware, where he continues to advance research in genetic therapies. His work has the potential to impact the treatment of genetic disorders significantly.

Collaborations

He collaborates with esteemed colleagues, including Eric B. Kmiec and Erin E. Brachman, who contribute to his research endeavors.

Conclusion

Hetal Parekh-Olmedo's innovative work in genetic therapeutics showcases his commitment to advancing medical science and improving treatment options for patients with genetic disorders. His contributions are paving the way for future breakthroughs in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…